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Management of thyroid nodules
on  US with benign or atypical
cytological features
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The  diagnosis  of  thyroid  nodule  is  based  on  the  ultra-
sound  examination  and  TIRADS  (Thyroid  Imaging  Reporting
and  Database  System),  which  classiﬁes  the  risk  of  malig-
nancy  according  to  ultrasound  criteria  [1].  This  determines
the  management  of  the  patient,  the  cornerstone  of  which  is
ultrasound-guided  ﬁne  needle  aspiration,  which  allows  the
thyroid  nodule  to  be  classiﬁed  into  one  of  six  cytological
categories  associated  with  a  risk  of  cancer  and  the  diag-
nostic  and  therapeutic  action  to  be  taken  according  to  the
Bethesda  reporting  system  of  2010  [2].  Highly  suspicious
TIRADS  ultrasound  signs  must  be  strictly  deﬁned  to  avoid
reducing  the  speciﬁcity  and  positive  predictive  value  of  the
score.
TIRADS  2  and  3  nodules  developing  in  a  suspicious  way
on  ultrasound
Some  benign  nodules,  initially  classiﬁed  as  stage  2  or  3
according  to  TIRADS,  may  be  remodeled  over  time  and
later  show  suspect  ultrasound  characteristics  (be  strongly
hypoechoic,  a  nodule  taller  than  wide,  the  presence  of
microcalciﬁcations,  irregular  margins),  thus  causing  them  to
be  classed  as  TIRADS  stage  4B  or  5  (Fig.  1).
Changes  can  be  spontaneous  or  secondary  to  needle  aspi-
ration  biopsy  or  percutaneous  ethanol  ablation  treatment
[3,4].  Cytological  analysis  can  be  ambiguous  (particularly
if  classiﬁed  as  atypia  of  undetermined  signiﬁcance  [AUS]
according  to  the  2010  Bethesda  system).  In  our  experi-
ence,  many  suspect  nodules  (TIRADS  4B  and  TIRADS  5)  are
ultimately  found  to  be  benign  (follow-up  and  successive
cytology,  pathological  anatomy).  In  our  opinion,  certain  fea-
tures  strongly  suggest  the  benign  nature  of  such  nodules:
some  of  them  have  a  suspect  part  (irregular  margins,  hypoe-
choic,  calciﬁed)  together  with  an  echogenic  part,  sometimes
in  the  form  of  a  cyst,  a  vestige  of  the  nodule  that  formerly
appeared  benign  (Fig.  2).  In  this  situation,  volume  reduction
is  frequent  and  no  lymphadenopathy  is  seen  in  the  drainage
sites.  Obviously  ﬁne  needle  aspiration  is  still  indicated.  If
the  cytological  results  include  atypia  of  undetermined  sig-
niﬁcance,  in  50%  of  cases  a  second  cytological  sample  will
allow  the  nodule  to  be  reclassiﬁed  as  benign.  If  the  sec-
ond  result  falls  into  the  AUS  category,  diagnostic  surgery
p
t
ts  generally  recommended.  However,  the  distinctive  ultra-
ound  structure  of  the  nodule  and  its  modiﬁcation  over  time
an  alert  the  radiologist  and  the  cytologist  to  the  possibil-
ty  of  a  remodeled  benign  nodule  and  allow  monitoring  with
nother  ﬁne  needle  aspiration  to  be  considered  instead  of
urgery  [5].
It  is  of  major  importance  to  compare  current  ultrasound
mages  with  the  previous  ones.  A  picture  archiving  and
ommunication  system  is  of  great  help  to  depict  changes
ver  time  to  reach  the  ﬁnal  diagnosis  of  remodeled  benign
odule.  Comparison  of  the  cytological  result  (AUS)  and  the
ood  quality  archive  image  (an  enlarged,  optimized  image)
ill  give  more  precise  clues  for  the  diagnosis.  Thus,  a  soft
US  nodule  (elastography  showing  no  stiffness  gradient  with
he  adjacent  thyroid  parenchyma)  will  be  highly  likely  to  be
enign  [6,7].  Conversely,  ﬁnding  highly  suspicious  ultrasound
riteria  (TIRADS  4B  and  TIRADS  5),  excluding  the  particular
ase  mentioned  above  of  a  nodule  evolving  towards  necro-
is,  will  more  strongly  suggest  the  possibility  of  a  thyroid
arcinoma  [8,9].
yperfunctioning  thyroid  nodules  posing  diagnostic
roblems  both  in  ultrasonography  and  cytology
hen  thyroid  stimulating  hormone  (TSH)  is  low  or  low  nor-
al  (<0.5  u/mL),  thyroid  scintigraphy  will  generally  show
he  benign  nature  of  the  hyperﬁxing  (hot)  nodule  showing
igns  of  hyperactivity  that  may  give  false  positives  for  malig-
ancy.
IRADS  4  nodules,  where  the  location  or  appearance
eads  to  searching  for  molecular  biology  markers  or
easurement  of  thyrocalcitonin
he  T1799A  (V600E)  mutation  activator  of  the  BRAF  gene
s  the  most  common  and  speciﬁc  oncogenic  factor  for  pap-
llary  carcinoma,  but  its  sensitivity  is  limited,  somewhere
etween  45%  and  50%.  Where  there  are  needle  aspiration
iopsy  atypia  (AUS),  particularly  in  the  cystic  form  with
 small  bell-like  cavity  or  the  follicular  variant,  the  pres-
nce  of  this  mutation  in  the  control  biopsy  liquid  indicates
 probable  papillary  neoplasia  and  de  facto  requires  surgery
10]. AFIRMA  Thyroid  FNA  Analysis  (AFIRMA),  which  allows
he  expression  of  142  different  genes  to  be  studied,  may
lso  determine  whether  indeterminate  cytology  is  or  is  not
uspicious  for  cancer  [11].
A  micronodule  located  in  the  middle  or  upper  third  of  the
hyroid  may  lead  to  medullary  thyroid  carcinoma  being  sus-
ected,  particularly  if  it  contains  echogenic  spots  suggesting
he  presence  of  amyloid  material  and  if  the  serum  calci-
onin  titer  is  raised  (sensitivity  in  the  order  of  98%)  (Fig.  3).
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Figure 1. A benign nodule evolving towards necrosis. An initially hyperechoic nodule with a small strongly hypoechoic peripheral portion
(star) (A). Two years later, the poorly delimited, hypoechoic part has increased (star) and has extended to the majority of the nodule
(B). Needle aspiration cytology has shown the presence of cell atypia (AUS according to Bethesda) probably related to necrosis. Another
follow-up ultrasound examination with a control needle aspiration biopsy shows that the nodule has remained stable in size with benign
cytology. There is a vestigial echogenic portion of the nodule of previously benign appearance.
Figure 2. Spontaneous desiccation of a benign nodule, with suspect ultrasound characteristics on follow-up. Right thyroid nodule (arrow),
completely encysted, measuring 20 mm in its longest axis, classed as TIRADS 2 (A). Nine months later, the same nodule had suspect ultrasound
characteristics (calciﬁcations, was markedly hypoechoic and had irregular margins) which meant that it was classed as TIRADS 5 (B) but had
greatly decreased in size (measuring 7 mm). The needle aspiration biop
benign.
Figure 3. Characteristics which should lead to a micro-medullary
thyroid carcinoma being suspected and to intra-nodular measure-
ment of the thyrocalcitonin concentration. Micronodule (7 mm)  with
irregular margins, located in the upper or middle third of a lobe
of the thyroid (never in the isthmus unless multifocal), containing
small hyperechoic spots (arrows) suggesting amyloid material. It
was a micro-medullary carcinoma where needle aspiration cytology
was ambiguous. In situ measurement of the calcitonin concentration
may help to diagnose this serious cancer at an early stage.
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n  the  case  of  microcarcinoma,  the  increase  in  serum  thyro-
alcitonin  may  nevertheless  be  very  limited  (15—100  pg/mL)
nd  needle  aspiration  cytology  remains  ambiguous  (AUS).  In
ddition,  concomitant  use  of  proton  pump  inhibitors  (PPI)
nd  a  patient  who  smokes  may  result  in  false  positive  labora-
ory  results.  In  certain  cases,  measuring  the  thyrocalcitonin
n  the  rinsing  liquid  will  permit  diagnosis  by  showing  a  very
igh  concentration  of  it  in  situ,  allowing  early  and  appropri-
te  surgery  [12].  This  measurement  should  thus  be  proposed
n  the  following  situations:  a  hypoechoic  nodule  the  vol-
me  of  which  has  been  shown  to  be  increasing  and  the
nitial  cytology  of  which  was  indeterminate,  having  amor-
hous  echogenic  deposits  (suggesting  amyloid  material)  and
erum  calcitonin  levels  which  are  not  conclusive  but  suspect
<100  pg/mL  with  the  kinetics  not  falling  after  stopping  PPIs
nd  tobacco),  particularly  if  there  is  a  family  history  of  MEN
ype  2.
In  conclusion,  precise  ultrasound  analysis  of  the  nodule
nd  its  evolution  over  time,  and  the  necessary  comparison
f  imaging  results  and  cytological  ﬁndings  limit  the  risks
f  false  negatives  and  false  positives  of  needle  aspiration
ytology.  Ultrasound  monitoring  of  a  suspect  thyroid  nodule
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with  repeat  needle  aspiration  biopsy  if  the  cytology  is  benign
or  AUS,  measurement  of  thyrocalcitonin  concentration  and
looking  for  genetic  markers  in  certain  selected  cases  should
improve  the  already  good  diagnostic  performance  of  the
radiologist/cytologist  team.
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